A validation study revealed the increased plasma EV levels of SHMT2 and SEMA3A proteins in patient-derived xenograft-bearing mice [126], supporting the clinical significance of IGF2BP1/SEMA3A-SHMT2 axis in neuroblastoma metastasis, which warrants further clinical studies of neuroblastoma liquid biopsy to inform therapeutic regimens against potential metastasis. The gene discussed is SEMA3A; the disease is neuroblastoma.